UK markets close in 1 hour 4 minutes
  • FTSE 100

    7,032.18
    -121.25 (-1.69%)
     
  • FTSE 250

    22,313.29
    -221.85 (-0.98%)
     
  • AIM

    1,231.92
    -9.45 (-0.76%)
     
  • GBP/EUR

    1.1654
    -0.0035 (-0.30%)
     
  • GBP/USD

    1.3822
    -0.0102 (-0.73%)
     
  • BTC-GBP

    26,627.85
    -1,419.49 (-5.06%)
     
  • CMC Crypto 200

    909.77
    -30.18 (-3.21%)
     
  • S&P 500

    4,182.52
    -39.34 (-0.93%)
     
  • DOW

    33,373.52
    -449.93 (-1.33%)
     
  • CRUDE OIL

    72.02
    +0.98 (+1.38%)
     
  • GOLD FUTURES

    1,774.30
    -0.50 (-0.03%)
     
  • NIKKEI 225

    28,964.08
    -54.25 (-0.19%)
     
  • HANG SENG

    28,801.27
    +242.68 (+0.85%)
     
  • DAX

    15,452.60
    -275.07 (-1.75%)
     
  • CAC 40

    6,571.58
    -94.68 (-1.42%)
     

​​​​​​​Eckert & Ziegler: Record Income Due to Sale of Division and Strong Core Business

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
  • Oops!
    Something went wrong.
    Please try again later.

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarter Results
17.05.2021 / 07:45
The issuer is solely responsible for the content of this announcement.

Berlin, 17 May 2021. One-off effects from the deconsolidation of the tumor irradiation business, a waning of the Corona slump, and continued strong demand in particular for pharmaceutical radioisotopes more than doubled net profit at Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700; TecDAX) in the first quarter of 2021. With sales revenues of 44 million EUR (PY: 44), the Berlin-based technology company posted a net profit of 13.8 million EUR, 8.8 million EUR more than in the same period of the previous year

6.8 million EUR of the quarterly profit were booked as a one-off in the Medical Segment due to the deconsolidation of the tumor irradiation business. Another 4.9 mm EUR of net income (36% more than last year) was generated in this segment in particular through stronger sales of pharmaceutical radioisotopes, but also of laboratory devices and nuclear production equipment. The performance in these sub-segments more than compensated a weak start in the project business (services for companies). The Industrial segment returned to pre-Corona profitability and closed the quarter with a net income of EUR 2.5 million. The holding, the group's third segment, where pre-clinical development expenses are booked, showed a loss of 0.4 mm EUR.

Although almost half (48%) of the 2021 annual income goal of EUR 29 million was already achieved in the first quarter, the Executive Board for now sticks to the guidance published in March due to the ongoing pandemic, the travel restrictions that continue to hamper business, and the extended delivery times for preliminary products, for example in plant construction.

The complete quarterly report can be viewed here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz121e.pdf

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with her 800 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com


17.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Eckert & Ziegler Strahlen- und Medizintechnik AG

Robert-Rössle-Str.10

13125 Berlin

Germany

Phone:

+49 30 941084-138

Fax:

+49 30 941084-112

E-mail:

karolin.riehle@ezag.de

Internet:

www.ezag.de

ISIN:

DE0005659700

WKN:

565970

Indices:

SDAX

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

EQS News ID:

1196935


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting